Securities



Chasing after Perodua

UMW Holdings has offered to acquire: (i) Med-Bumikar's 50.1%interest in MBM Resources Berhad (MBM) for RM501m (RM2.56 per share); and (ii) PNB's 10%-stake in Perodua for RM418m. These acquisitions, if materialised, will boost UMWH's stake in Perodua to 70.6%, from 38%. We view the proposed acquisition of MBM as a winwin deal - it enables UMWH to raise its stake in Perodua at sensible price, thereby strengthening its position in the Malaysia automotive market. Meanwhile, MBM shareholders' have the opportunity to exit its manufacturing businesses that have seen lacklustre growth. That said, the offer price for MBM (RM2.56) looks unattractive. No change in our valuation and recommendations for UMWH (SELL) and MBM (HOLD).

UMWH has made two separate acquisitions offers:

- The first offer involves the purchase of a 50.07% stake in MBM from Med-Bumikar Sdn Bhd for RM501m. The acquisition will trigger a mandatory offer (MO) for the remaining shares in MBM. UMW does not intend to maintain the listing of MBM post MO. MBM currently holds an effective 22.58%-stake in Perodua.
- Separately, UMWH has offer to acquire a 10%-stake in Perodua from Permodalan Nasional Bhd (PNB) for RM417.5m, to be paid by new shares and cash (Fig 1). The deal values Perodua at RM4.2bn.

The UMWH-MBM acquisition, in our view, looks unattractive

For UMWH shareholders, the proposed acquisition values MBM at 30% discount to its net asset of RM3.68 per share (as at end-Dec 2017). Assuming a fair value of RM943m for MBM's 22.6%-stake in Perodua (using the UMWH-PNB deal as benchmark), UMWH offers an effective RM141m (adjusted for RM83m net borrowings) for MBM's manufacturing business, facilities and office buildings (Menara MBMR).

For MBM, the offer enables the shareholders to exit their investment. Aside from Perodua, MBM's core manufacturing businesses are facing headwinds (challenging market condition, manufacturing issues at its alloy plant) and has reported operating losses in 2017A. **However, the offer price of RM2.56 looks unattractive** – it values MBM at a 30% discount to its net asset per share and also, the RM4.2bn implied price tag values Perodua at 9x 2016 PER, which seems low for the country's leading auto company.

Offer price may be a point of contention

The offers to Med-Bumikar (MBM's major shareholder) and PNB will remain open for acceptance until 5pm on 28th March 2018. While we see plenty of merits for the UMWH-MBM deal, we have little visibility on whether MBM's major shareholder would accept the offer. The offer price, we believe, will be an important consideration, along with industry outlook.

No change to our call on UMWH (SELL) and MBM (HOLD)

We reaffirm our SELL call on UMWH with a target price of RM5.08. UMWH has a market cap of RM6.95bn, pegging its 38%-stake in Perodua at RM1.6bn (implied from its offer price to PNB), its other businesses (motor trading, industrial, manufacturing, unprofitable oil & gas) has an implied market price of RM5.4bn, which looks stretched. Elsewhere, we maintain our HOLD call on MBM with an unchanged TP of RM2.27 for now, as the proposed acquisition is at its preliminary stages and the outcome is still uncertain.

Affin Hwang Investment Bank Bhd (14389-U)

Out think. Out perform.

Sector Update

Auto & Autoparts

NEUTRAL (maintain)

Absolute Performance (%)				
	1M	3M	12M	
APM MK	-4.2	0.3	-5.7	
MBM MK	-3.1	0.9	-12.0	
UMWH MK	-9.8	18.3	11.6	
SIME MK	-4.8	22.2	24.2	
PECCA MK	-3.0	-14.4	-18.1	

Relative Performance (%)



Brian Yeoh (603) 2146 7658 Brian.yeoh@affinhwang.com

Securities



Out think. Out perform.


Fig 1: Proposal summary

Target	Consideration	Perodua Stake (%)
MBM Resources Bhd	RM2.56/share	22.6
PNB Equity Resource Corp Sdn Bhd	Issue of RM42.9 new UMWH shares at RM6.09; Cash of RM117.5m	10.0

Source: Company, Affin Hwang


Fig 2 & 3: Group structure before and after the proposal

As at 6 March 2018^(a)



Source: Company

Fig 4: Perodua's historical net profit




Source: Company

48.0%

After the Proposals

Fig 5: Perodua hits highest monthly sales market share of 40%

1M18 Market Share



oposal

Securities



Important Disclosures and Disclaimer

Out think. Out perform.

Equity Rating Structure and Definitions

BUY	Total return is expected to exceed +10% over a 12-month period	
HOLD	Total return is expected to be between -5% and +10% over a 12-month period	
SELL	Total return is expected to be below -5% over a 12-month period	
NOT RATED	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation	
The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.		
OVERWEIGHT	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months	
NEUTRAL	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months	
UNDERWEIGHT	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months	

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors and/or employees may have an interest in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by: Affin Hwang Investment Bank Berhad (14389-U) A Participating Organization of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead, 69, Jalan Raja Chulan, 50200 Kuala Lumpur, Malaysia.

T : + 603 2142 3700 F : + 603 2146 7630 research@affinhwang.com

www.affinhwang.com